CD19 and graft versus host disease: In summary, these data demonstrate that our HIP CAR T cells are effective immune therapeutics against CD19+ tumors, have a reduced risk of GVHD, and have the ability to escape both adaptive and innate immunity for improved persistence in allogeneic recipients.